Liquidia Corp (LQDA) Q4 2025 Earnings Call

Concluded Mar 5, 2026

Mar 5, 2026 0 turns

Period: FY2025 Q4
Runtime: —
Sources: 2 artifacts

8-K 10-K

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.

YUTREPIA Commercial Launch 58 Disease Area Expansion 34 Pipeline and Clinical Expansion 15 Competitive Landscape 12 Market Share Growth 11 Transition from Other Therapies 11

Management tone

Confident

Net tone +82 · low hedging

Grounding quotes

“Liquidia is now operating as a cash-generating growth engine. That is not aspirational; it is visible in the quarterly numbers and on the balance sheet.”
“The momentum of 2025 has clearly carried into 2026. As of February 28, we have received more than 3,600 unique patient referrals and shipped therapy for more than 2,900 patients since launch, maintaining our robust trajectory.”
“we are very confident in our growth trajectory as we head into 2026 and 2027”
“We're confident in 2026 and the years ahead as we focus on building a durable franchise with increasing patient preference and a clear path towards at least a $1 billion franchise in 2027 with increasing growth in the years beyond.”

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Revenue · derived Q4 $92.02M +3054.6% YoY

Net income · derived Q4 $14.55M

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Mar 5, 2026 10-K report Filed Mar 5, 2026 Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →